4 February 2025 in The FASEB Journal
Retinal neovascularization impairs visual function and is a hallmark of several neovascular eye diseases, including retinopathy of prematurity (ROP) and proliferative diabetic retinopathy (PDR). Current treatments include intravitreal injections of anti‐vascular endothelial growth factor (VEGF) biologics, but these therapeutics are often accompanied by high treatment burden and resistance to therapy. Prior studies indicate that APE1/Ref‐1, a multifunctional protein with both endonuclease (APE1) and redox‐mediated transcriptional regulatory activity (Ref‐1), activates multiple pro‐angiogenic and pro‐inflammatory signaling pathways by chemically reducing key cysteine residues in transcription factors, thereby activating them. Here, we investigated the previously unexplored role of Ref‐1 in retinal neovascularization. We demonstrate that Ref‐1 is highly expressed in endothelial cells in human PDR and in the oxygen‐induced retinopathy (OIR) mouse model of retinal neovascularization. Ref‐1 is also highly expressed in microglia and astrocytes in OIR. A small molecule Ref‐1 redox inhibitor, APX2009, decreased retinal neovascularization in OIR after systemic delivery. In vitro, hypoxic endothelial cells did not exhibit upregulation of Ref‐1 but rather increased Ref‐1 nuclear localization. APX2009 decreased hypoxic endothelial cell proliferation and HIF‐1α transcriptional activation. Thus, Ref‐1 redox activity may be a novel therapeutic target for the treatment of retinal neovascularization, making APX2009 a promising systemic therapeutic approach for the treatment of vascular retinopathies such as ROP and PDR.
17 September 2026 in Antioxidants & Redox Signaling
Aims: Apurinic/apyrimidinic endonuclease 1/redox effector factor 1 (APE1/Ref-1) is a multifunctional protein implicated in pancreatic ductal adenocarcinoma (PDAC) through its redox regulation of oncogenic transcription factors (TFs) such as hypoxia-inducible factor 1-alpha, nuclear factor kappa-light-chain-enhancer of activated B cells, and others. While Cys65 is recognized as the primary redox-active residue, the functions of other cysteines remain only partially understood. Here, we describe the first CRISPR-engineered homozygous PDAC cell lines with single (C93A, C99A) and double (C93A + C99A) Ref-1 point mutations. This enabled detailed analysis of the individual and combined roles of Cys93 and Cys99 in Ref-1 redox signaling and their impact on various cancer phenotypes. Results: A single mutation at Cys93 decreased TF activation and reduced tumor cell survival in vitro and in vivo . These effects were similar but less pronounced in cells expressing C99A. The C93A + C99A double mutant further impaired redox signaling and decreased tumor growth and metastasis in orthotopic PDAC mouse models. All of these perturbations specifically disrupted Ref-1’s redox activity without impacting its DNA repair function. Due to reduced levels of Ref-1 protein in the C93A + C99A tumor cells, add-back experiments with wild-type Ref-1 and C93A + C99A-Ref-1 examined the impact on cell survival and activation of TFs downstream of Ref-1. Transcriptomic analysis revealed distinct changes in redox and metabolic pathways, although these were less pronounced than those observed with the previously studied C65A mutant. Innovation and Conclusion: These findings demonstrate contributory and cooperative, although secondary, roles for Cys93 and Cys99 in Ref-1 redox activity, establish new genetically engineered PDAC models, and underscore the therapeutic potential of targeting Ref-1 redox function in PDAC. Antioxid. Redox Signal. 00, 000–000.
10 December 2021 in Proceedings of IMPRS
APE1/Ref-1 (apurinic/apyrimidinic endonuclease-redox effector factor 1) is a multifunctional protein that has been shown to be overexpressed in multiple types of cancer. The overexpression of APE1/Ref-1 is linked to higher cancer cell survival and increased patient mortality. Furthermore, APE1/Ref-1 is a key regulator of transcription factors (TF) through redox signaling and protein-protein interaction. It is involved in proliferative and inflammatory signaling upregulated in cancer. Transcription factor NF-kB is involved in inflammatory cytokine expression and has been shown to be regulated by Ref-1. My project investigated how Ref-1 regulates NF-kB, specifically Rel-A, in a model using K-rasLSL.G12D/+; Pdx-1-Cre (KC) pancreatic tumor cells (KC3590) derived from genetically engineered mice. Additionally, I explored other TFs within the APE1/Ref-1 signaling pathway, such as STAT3, in this model. My work involved knocking down STAT3 levels within four variations of the KC3590 line. These were the KC3590/ΔNF-kB (parent) and KC3590/ΔNF-kB vector lines (vector) which contain exon deletions within the NF-kB gene rendering it nonfunctional. KC3590/13 and KC3590/15 are cell lines which are KC3590/ΔNF-B cells with functional full-length NF-kB added to the cells. Previous experiments demonstrated that the ΔNF-kB and ΔNF-kB vector lines are resistant to treatment by the specific Ref-1 inhibitors, including APX3330, which inhibit the redox signaling function of Ref-1. Initial data demonstrated that adding back functional NF-kB to the NF-kB deficient cells reestablished sensitivity to APX3330, presumably due to the reintroduction of the Ref-1 target, NF-kB. Knockdown of STAT3 expression in the ΔNF-kB and ΔNF-kB vector lines demonstrated some sensitivity to APX3330, however, in the C13/15 cell lines, no enhanced sensitivity was observed. These data support the hypothesis that NF-kB is the major TF driving the growth of KC pancreatic tumor cells. Subsequent studies will clarify further the role of APE1/Ref-1 regulation in the KC model and the relative importance of APE1/Ref-1’s target TFs.
10 February 2025 in The FASEB Journal